TCM Ltd Q1 Results: Net loss narrows, revenue up 32% YoY
TCM Limited reported a standalone net loss of ₹121.69 lakh for Q1FY27, down from ₹147.88 lakh in the prior year. Consolidated revenue rose 52% YoY to ₹487.97 lakh, driven by manufacturing and real estate segments. Finance costs increased 35%, impacting profitability despite top-line growth.
*this image is generated using AI for illustrative purposes only.
TCM Limited reported a narrowing of losses and significant revenue growth for the first quarter of FY27. The company posted a standalone net loss of ₹121.69 lakh for the quarter ended June 30, 2026, compared to a net loss of ₹147.88 lakh in the corresponding period of FY26. On a consolidated basis, the group recorded a net loss of ₹160.13 lakh, down from ₹235.26 lakh in Q1FY26.
Revenue from operations expanded sharply, reflecting improved operational activity across key segments. Standalone revenue rose 32% year-on-year to ₹402.01 lakh, up from ₹304.87 lakh in Q1FY26. Consolidated revenue grew even more robustly by 52% to ₹487.97 lakh, compared to ₹320.97 lakh in the prior year quarter.
Segment Performance
The company’s diversified portfolio saw mixed results, with the trading segment emerging as a key profit contributor while manufacturing faced headwinds.
| Segment | Consolidated Revenue (₹ Lakh) | Consolidated Result (₹ Lakh) |
|---|---|---|
| Trading | 89.73 | 30.87 |
| Manufacturing | 308.61 | (37.22) |
| Educational | 59.38 | 2.61 |
| Real Estate | 30.25 | 12.54 |
The trading segment, which includes solar, healthcare, autocare, and audio products, delivered a positive segment result of ₹30.87 lakh, a significant improvement from a loss of ₹72.74 lakh in Q1FY26. Conversely, the manufacturing segment, despite contributing the largest share of revenue at ₹308.61 lakh, incurred a segment loss of ₹37.22 lakh, widening from a profit of ₹22.79 lakh in the same period last year. The real estate segment contributed ₹12.54 lakh to the bottom line, while the educational unit reported a modest profit of ₹2.61 lakh.
What the Numbers Show
A critical divergence exists between top-line growth and bottom-line performance. While consolidated revenue surged 52% year-on-year, total expenses increased by 16% to ₹653.85 lakh. More notably, finance costs rose 35% to ₹52.16 lakh from ₹38.54 lakh in Q1FY26. This disproportionate rise in interest expenses relative to revenue growth indicates that debt servicing costs are currently outpacing operational leverage, limiting the translation of higher sales into profitability.
Corporate Developments
During its board meeting held on August 13, 2026, TCM Limited approved several administrative matters alongside the financial results. The board recommended the reappointment of independent directors Mr. Gopalakrishnan Mahesh and Mr. Jose Jacob for a second term of five years, subject to shareholder approval at the upcoming annual general meeting. The 82nd Annual General Meeting is scheduled for September 25, 2026.
The unaudited financial results were reviewed by S G M & Associates LLP, the statutory auditors, who issued a limited review report stating that nothing came to their attention to cause them to believe the statements contained material misstatements.
Historical Stock Returns for TCM
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.12% | -6.52% | +1.42% | -19.13% | +11.23% | +12.18% |
What specific operational strategies is TCM Limited implementing to reverse the profitability trend in its manufacturing segment, which now incurs losses despite being the largest revenue contributor?
How does the 35% surge in finance costs impact the company's debt restructuring plans, and will management prioritize deleveraging to improve bottom-line margins in FY27?
Given the trading segment's turnaround from a significant loss to a profit, what market dynamics or product mix changes drove this improvement, and is this growth sustainable?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
